Kate Chang
Amicus Therapeutics (United States)(US)
Publications by Year
Research Areas
Lysosomal Storage Disorders Research, Glycogen Storage Diseases and Myoclonus, Parkinson's Disease Mechanisms and Treatments, Urinary Bladder and Prostate Research, Sexual function and dysfunction studies
Most-Cited Works
- → Coformulation of a Novel Human α -Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice(2015)36 cited
- → Glucosylceramide Quantitation in Normal and Glucocerebrosidase-Deficient Mouse Brain and Human Cell Lines(2012)5 cited
- → Novel recombinant human acid α-glucosidase with optimal glycosylation is significantly better than standard of care enzyme replacement for glycogen clearance in skeletal muscles of GAA knock-out mice(2015)5 cited
- → Pharmacological chaperones aren't just for mutant enzymes anymore: Co-administration of AT1001 Stabilizes rh∂-Gal A, leading to greater uptake and substrate reduction in fabry patient-derived cells and GLA knockout mice(2011)
- Formanilide inhibition of house fly acetylcholinesterase.(1980)
- → Histological examination of the effect of a highly phosphorylated proprietary recombinant human acid alpha-glucosidase on glycogen reduction in disease-relevant muscles of Pompe mice(2015)
- → Co-administration of the pharmacological chaperone AT2221 with a proprietary recombinant human acid alfa-glucosidase leads to greater plasma exposure and substrate reduction compared to alglucosidase alfa(2016)
- → 13. A pharmacogenetic approach to pharmacological chaperonetherapy for Fabry disease(2010)